MX2019009586A - Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. - Google Patents
Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.Info
- Publication number
- MX2019009586A MX2019009586A MX2019009586A MX2019009586A MX2019009586A MX 2019009586 A MX2019009586 A MX 2019009586A MX 2019009586 A MX2019009586 A MX 2019009586A MX 2019009586 A MX2019009586 A MX 2019009586A MX 2019009586 A MX2019009586 A MX 2019009586A
- Authority
- MX
- Mexico
- Prior art keywords
- permeability
- compositions
- methods
- disease associated
- treating disease
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000004347 intestinal mucosa Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000035699 permeability Effects 0.000 title 1
- ORFLZNAGUTZRLQ-ZMBVWFSWSA-N Larazotide Chemical compound NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O ORFLZNAGUTZRLQ-ZMBVWFSWSA-N 0.000 abstract 2
- 230000004064 dysfunction Effects 0.000 abstract 1
- 210000005027 intestinal barrier Anatomy 0.000 abstract 1
- 230000007358 intestinal barrier function Effects 0.000 abstract 1
- 230000003870 intestinal permeability Effects 0.000 abstract 1
- 229950000060 larazotide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457279P | 2017-02-10 | 2017-02-10 | |
| PCT/US2018/017813 WO2018148655A1 (en) | 2017-02-10 | 2018-02-12 | Compositions and methods for treating disease associated with permeability of intestinal epithelium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009586A true MX2019009586A (es) | 2019-11-11 |
Family
ID=63107916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009586A MX2019009586A (es) | 2017-02-10 | 2018-02-12 | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11058902B2 (https=) |
| EP (2) | EP3579862A4 (https=) |
| JP (1) | JP2020507626A (https=) |
| KR (1) | KR20190121785A (https=) |
| CN (1) | CN110891587A (https=) |
| AU (1) | AU2018219367A1 (https=) |
| BR (1) | BR112019016705A2 (https=) |
| CA (1) | CA3052975A1 (https=) |
| MX (1) | MX2019009586A (https=) |
| WO (2) | WO2018148655A1 (https=) |
| ZA (1) | ZA201905439B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11058902B2 (en) * | 2017-02-10 | 2021-07-13 | 9 Meters Biopharma, Inc. | Compositions and methods for treating disease associated with permeability of intestinal epithelium |
| WO2019165346A1 (en) | 2018-02-23 | 2019-08-29 | Innovate Biopharmaceuticals, Inc. | Compounds and methods for treating tight junction permeability |
| US20210100868A1 (en) * | 2018-03-19 | 2021-04-08 | North Carolina State University | Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy |
| WO2019183036A1 (en) | 2018-03-19 | 2019-09-26 | Innovate Biopharmaceuticals, Inc. | Compositions and methods for potentiating immune checkpoint inhibitor therapy |
| WO2021034629A1 (en) * | 2019-08-16 | 2021-02-25 | 9 Meters Biopharma, Inc. | Larazotide formulations |
| AU2021255955A1 (en) * | 2020-04-15 | 2022-11-10 | Interlude Biopharma Co. | Larazotide derivatives comprising d-amino acids |
| WO2023154770A1 (en) * | 2022-02-09 | 2023-08-17 | 9 Meters Biopharma, Inc. | Compositions and methods for inhibiting rho kinase |
| CN114788837B (zh) * | 2022-06-07 | 2023-09-05 | 青岛东海药业有限公司 | 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665389A (en) | 1995-05-24 | 1997-09-09 | University Of Maryland At Baltimore | Oral dosage composition for intestinal delivery and method of treating diabetes |
| US5827534A (en) | 1995-05-24 | 1998-10-27 | University Of Maryland At Baltimore | Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery |
| US5945510A (en) | 1997-05-21 | 1999-08-31 | University Of Maryland, Baltimore | Substantially pure zonulin, a physiological modulator of mammalian tight junctions |
| US6458925B1 (en) | 1998-08-03 | 2002-10-01 | University Of Maryland, Baltimore | Peptide antagonists of zonulin and methods for use of the same |
| AU2001249067A1 (en) | 2000-05-19 | 2001-12-03 | University Of Maryland, Baltimore | Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes |
| US20060062758A1 (en) * | 2004-09-21 | 2006-03-23 | Nastech Pharmaceutical Comapny Inc. | Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds |
| US20090176244A1 (en) | 2005-05-13 | 2009-07-09 | Bai Julio | Methods and compositions for the diagnosis of crohn's disease |
| CN101189518A (zh) * | 2005-05-13 | 2008-05-28 | 马里兰巴尔的摩大学 | 评价治疗方案有效性的方法 |
| AR057058A1 (es) * | 2005-06-09 | 2007-11-14 | Alba Therapeutics Corp | Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas |
| MX2008010221A (es) * | 2006-02-09 | 2009-03-05 | Alba Therapeutics Corp | Formulaciones para un efector de union ajustada. |
| WO2008043107A2 (en) | 2006-10-06 | 2008-04-10 | Alba Therapeutics Corporation | Use of tight junction antagonists to treat inflammatory bowel disease |
| US8034776B2 (en) | 2006-10-26 | 2011-10-11 | Alba Therapeutics Corporation | Materials and methods for the treatment of celiac disease |
| US20110201543A1 (en) | 2007-06-29 | 2011-08-18 | Blake Paterson | Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress |
| US8198233B2 (en) | 2007-07-26 | 2012-06-12 | Alba Therapeutics Corporation | Synthetic peptides that enhance tight junction permeability |
| WO2009052489A2 (en) | 2007-10-19 | 2009-04-23 | Alba Therapeutics Corporation | Novel inhibitors of mammalian tight junction opening |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| CN101440369A (zh) * | 2008-03-26 | 2009-05-27 | 华东师范大学 | 一种缺失的霍乱弧菌封闭带毒素的表达方法及应用 |
| WO2009137572A2 (en) * | 2008-05-06 | 2009-11-12 | Alba Therapeutics Corporation | Inhibition of gliadin peptides |
| WO2010042821A1 (en) * | 2008-10-10 | 2010-04-15 | Nationwide Children's Hospital | Method of treating necrotizing enterocolitis using heparin binding epidermal growth factor |
| EP3125870A4 (en) * | 2014-04-04 | 2017-12-13 | Alba Therapeutics Corporation | Methods of treating celiac disease with larazotide |
| CA2955425A1 (en) * | 2014-07-17 | 2016-01-21 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
| US11058902B2 (en) * | 2017-02-10 | 2021-07-13 | 9 Meters Biopharma, Inc. | Compositions and methods for treating disease associated with permeability of intestinal epithelium |
-
2018
- 2018-02-12 US US16/484,497 patent/US11058902B2/en active Active
- 2018-02-12 JP JP2019564370A patent/JP2020507626A/ja active Pending
- 2018-02-12 US US16/484,486 patent/US20190358288A1/en not_active Abandoned
- 2018-02-12 BR BR112019016705A patent/BR112019016705A2/pt not_active Application Discontinuation
- 2018-02-12 WO PCT/US2018/017813 patent/WO2018148655A1/en not_active Ceased
- 2018-02-12 KR KR1020197026186A patent/KR20190121785A/ko not_active Ceased
- 2018-02-12 AU AU2018219367A patent/AU2018219367A1/en not_active Abandoned
- 2018-02-12 CN CN201880022687.5A patent/CN110891587A/zh active Pending
- 2018-02-12 MX MX2019009586A patent/MX2019009586A/es unknown
- 2018-02-12 EP EP18750723.1A patent/EP3579862A4/en active Pending
- 2018-02-12 WO PCT/US2018/017811 patent/WO2018148654A1/en not_active Ceased
- 2018-02-12 CA CA3052975A patent/CA3052975A1/en active Pending
- 2018-02-12 EP EP18751409.6A patent/EP3579863A4/en not_active Withdrawn
-
2019
- 2019-08-16 ZA ZA2019/05439A patent/ZA201905439B/en unknown
-
2021
- 2021-06-10 US US17/344,172 patent/US20210299481A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210299481A1 (en) | 2021-09-30 |
| EP3579862A1 (en) | 2019-12-18 |
| CN110891587A (zh) | 2020-03-17 |
| WO2018148655A1 (en) | 2018-08-16 |
| CA3052975A1 (en) | 2018-08-16 |
| ZA201905439B (en) | 2021-02-24 |
| EP3579863A4 (en) | 2020-11-11 |
| US20190358288A1 (en) | 2019-11-28 |
| BR112019016705A2 (pt) | 2020-04-07 |
| EP3579863A1 (en) | 2019-12-18 |
| US20190358289A1 (en) | 2019-11-28 |
| US11058902B2 (en) | 2021-07-13 |
| JP2020507626A (ja) | 2020-03-12 |
| WO2018148654A1 (en) | 2018-08-16 |
| AU2018219367A1 (en) | 2019-09-19 |
| KR20190121785A (ko) | 2019-10-28 |
| EP3579862A4 (en) | 2020-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
| PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
| ZA201903091B (en) | Methods of treating inflammatory conditions | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| ZA201804513B (en) | Method of treating c3 glomerulopathy | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| PH12015502773A1 (en) | Methods for treating or preventing opthalmological conditions | |
| MX2017002374A (es) | Composiciones y metodos para tratar trastornos de la vision. | |
| ZA202000375B (en) | Compounds for the prevention and treatment of medical disorders and uses thereof | |
| MX2020002802A (es) | Anticuerpos de cadena pesada que se unen a ectoenzimas. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX388592B (es) | Compuestos y metodos terapeuticos. | |
| PH12019502315A1 (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| IL280952A (en) | Methods and drug compounds for the treatment of ophthalmic diseases | |
| MY205171A (en) | Methods of treatment of hypertriglyceridemia | |
| MX370436B (es) | Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica. | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. |